Our vendors directory lists research suppliers and manufacturers that may supply it, with community ratings, COA access, testing standards, and shipping options so you can compare before you order
Yes, GLP-1 medications are now FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related health condition, independent of a diabetes diagnosis
doi:10.1016/0006-2952(92)90140-E
Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
Guaranteed Outcomes Our premium plan guarantees up to 10% weight loss in six months or your money back
